
AstraZeneca drug for SLE patients approved in the EU
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. Context Saphnelo is the first biologic for SLE approved in… Read More
